The obesity branch at Profil is familiar with all aspects of obesity/adiposity research with particular emphasis on comorbidities such as impaired glucose metabolism in terms of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG).
IGT and IFG are intermediate conditions in the transition phase of normality and diabetes, also referred to as prediabetes. Because there are no symptoms of IGT and IGF, many people have the condition and are unaware of it. Prediabetes as well as diabetes meet established criteria for conditions in which early detection is appropriate. Both conditions are common, are increasing in prevalence, and impose significant health burdens.
The American Diabetes Association (ADA) defines special categories at increased risk for diabetes (prediabetes):
People with IGT or IFG are at hight risk of the progression to type 2 diabetes. Both conditions are associated with obesity (especially abdominal or visceral obesity), dyslipidemia with high triglycerides and/or low HDL cholesterol, and arterial hypertension.
![]() ISO 13485:2016
|
![]() ISO 9001:2015
|
Kapitza, C. et al. 2017. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017 Aug;60(8):1390-1399.